Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · IEX Real-Time Price · USD
24.13
-0.57 (-2.31%)
Apr 30, 2024, 4:00 PM EDT - Market closed
Avidity Biosciences Revenue
In the year 2023, Avidity Biosciences had annual revenue of $9.56M with 3.64% growth. Revenue in the quarter ending December 31, 2023 was $2.19M, a -20.80% decrease year-over-year.
Revenue (ttm)
$9.56M
Revenue Growth
+3.64%
P/S Ratio
201.22
Revenue / Employee
$37,787
Employees
253
Market Cap
1.92B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 9.56M | 336.00K | 3.64% |
Dec 31, 2022 | 9.22M | -102.00K | -1.09% |
Dec 31, 2021 | 9.33M | 2.54M | 37.41% |
Dec 31, 2020 | 6.79M | 4.47M | 192.67% |
Dec 31, 2019 | 2.32M | 1.94M | 511.87% |
Dec 31, 2018 | 379.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Owens & Minor | 10.33B |
Galapagos NV | 266.36M |
Ginkgo Bioworks Holdings | 251.46M |
RxSight | 89.08M |
Recursion Pharmaceuticals | 44.58M |
Intellia Therapeutics | 36.28M |
NewAmsterdam Pharma Company | 15.66M |
RNA News
- 8 days ago - Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 4 weeks ago - Avidity Biosciences to Participate in Upcoming Investor Conferences - PRNewsWire
- 2 months ago - Avidity Biosciences Honors Rare Disease Day® - PRNewsWire
- 2 months ago - Avidity Biosciences Announces Oversubscribed $400 Million Private Placement - PRNewsWire
- 2 months ago - Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights - PRNewsWire
- 4 months ago - Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth - PRNewsWire
- 5 months ago - Avidity Stock Soars on Collaboration Deal With Bristol Myers - Barrons
- 5 months ago - Avidity's stock soars on news of expanded collaboration with Bristol Myers that includes potential to receive up to $2.2 billion in milestone payments - Market Watch